Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iodine-131 basiliximab radioimmunotherapy for relapsed or refractory CD25-positive lymphoproliferative malignancies
ACTRN12605000802606Phase 2Recruiting
- Sponsor
- South Metropolitan Health Service
- Start
- Mar 2006
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iodine-131 basiliximab in lymphoproliferative disorder (LPD), Hodgkin lymphoma (HL) and lymphoma, sponsored by South Metropolitan Health Service. Primary endpoints: Safety, Efficacy and 1 more. Started Mar 2006; status: recruiting.
02
Drugs
iodine-131 basiliximab
03
Conditions
lymphoproliferative disorder (LPD)Hodgkin lymphoma (HL)lymphoma
Beyond the preview
Go deeper on ACTRN12605000802606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000802606.